Amiodarone Liver Toxicity Guidelines

Incidence and Clinical Presentation

The American Academy of Family Physicians recommends that liver toxicity from amiodarone is common but usually mild, occurring at a rate of 0.6% annually in patients on long-term therapy, and the drug should be discontinued if liver enzymes rise to three times the upper limit of normal unless the patient is at high risk for life-threatening arrhythmia recurrence 1
Clinically significant liver toxicity manifested by elevated liver transaminase levels occurs at 0.6% annually during long-term oral therapy, according to the American Academy of Family Physicians 1, 2, 3
Patients are rarely symptomatic despite biochemical abnormalities, which is why routine monitoring is essential, as recommended by the American Academy of Family Physicians 1, 2

The American Heart Association suggests that IV amiodarone carries higher acute risk, particularly with low ejection fraction and higher loading dose concentrations and faster infusion rates than recommended 4
Oral amiodarone risk may correlate with cumulative dose exposure, according to the American College of Cardiology 5

The American Academy of Family Physicians recommends baseline assessment, including liver transaminase levels and complete history and physical examination, before starting amiodarone therapy 1, 4, 5
During therapy, the American Academy of Family Physicians suggests monitoring liver transaminase levels every 6 months for oral therapy and closely during IV administration 1, 4, 5
If liver enzymes are ≥3× upper limit of normal, the American College of Cardiology recommends discontinuing amiodarone immediately unless the patient is at high risk for recurrence of life-threatening arrhythmia 1, 2, 3, 5

The American Heart Association states that for mortality and quality of life, the decision to continue or discontinue amiodarone hinges on whether the patient has life-threatening arrhythmias that are refractory to other treatments and the degree of liver enzyme elevation 1, 2, 3